In vitro Selection of the 2'-Fluoro-2'-Deoxyribonucleotide Decoy RNA Inhibitor of Myasthenic Autoantibodies

  • Published : 2000.10.01

Abstract

Myasthenia gravis (MG) is caused mainly by autoantibodies directed against acetylcholine receptors located in the postsynaptic muscle cell membrane. Using in vitro selection techniques, we isolated an RNA containing 2'-fluoro pyrimidines that can specifically and avidly ($K_d$ ~25 nM) bind rat monoclonal antibody called mAb198, which recognizes the main immunogenic region on the acetylcholine receptors. This RNA can act as a very effective decoy and block mAb198 binding to the receptors in vitro. Furthermore, this RNA decoy can prevent the antigenic modulation of the acetylcholine receptor caused by mAb198 in human muscle cell cultures with and $IC_{50} $of approximately $2.4{\mu}M$. These results indicate that the RNA selected in this study is a more potent decly inhibitor of myashthenic antibodies than the previously identified RNA with 2'-amino pyrimidines [11]. Moreover, this RNA cross-reacts with autoantibodies from patients with MG and can protect human cells from the effects of these antibodies. These observations have important implications for developing an antigen-specific treatment of autoimmune diseases including MG, which is based on decoy RNAs selected in vitro.

Keywords

References

  1. Biochemistry v.31 2'-Fluoro-and 2'-amino-2'-deoxynucleoside 5'-triphosphates as substrates for T7 RNA polymerase Aurup, H.;D. M. Williams;F. Eckstein
  2. Proc. Natl. Acad. Sci.USA v.92 Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor Daudna, J.;T. R. Cech;B. A. Sullenger
  3. N. Engl. J. Med v.330 Myasthenia gravis Drachman, D. B.
  4. The RNA World RNA: The shape of things to come Gold, L;P. Allen;J. Binkley;D. Brown;D. Schneider;S. R. Eddy;C. Tuerk;L. Green;S. Macdougal;D. Tasset;R. F. Gestelend(ed.);J. F. Atkins(ed.)
  5. Annu. Rev. Biochem v.64 Diversity of oligonucleotide functions Gold, L.;B. Polisky;O. C. Uhlenbeck;M. Yatus
  6. J. Immunol v.158 Human antinicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies Graus, Y. F.;M. H. de Baets;P. Parren;S. Berrih-Aknin;J. Wokke;P. Vriesman;D. R. Burton
  7. J. Microbiol. Biotechnol v.9 Identification of an embryonic growth factor IGF-Ⅱ from the central nervous system of the teleost, flounder, and its expressions in adult tossues Kim, D. S.;Y. T. Kim
  8. J. Virol. v.68 Inhibition of HIV-1 in human T-cells by a potent RRE decoy comprised of the 13 nucleotide-long minimal rev binding domain Lee, S.-W.;H. Gallardo;E. Gilboa;C. Smith
  9. Gene Ther. v.2 Inhibition of HIV-1 in CEM cells by a potent TAR decoy Lee, S.-W.;H. Gallardo;O. Gasper;C. Smith;E. Gilboa
  10. J. Exp. Med v.194 Isolation of a nuclease resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes Lee, S.-W.;B. Sullenger
  11. Nature Biotechnol v.15 Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies Lee, S-W.;B. Sullenger
  12. J. Microbiol v.36 Studies on the inhibition of HIV replication with a number of RRE decoy derivatives Lee, S.-W.
  13. J. Immunol v.146 Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis Lennon, V. A.;E. H. Lambert;K. R. Leiby;T. B. Okarma;S. Talib
  14. Adv. Immunol v.42 Myasthenia gravis Lindstrom, J.;D. Shelton;Y. Fugii
  15. J. Neurosci. v.9 A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671 Luther, M. A.;R. Schoepfer;P. Whiting;B. Casey;Y. Blatt;M. S. Montal;M. Montal;J. Lindstrom
  16. Eur. J. Immunol v.23 Bacterial expression of a single-chain Fv fragment which efficiently protects the acetylcholine receptor against antigenic modulation caused by myasthenic antibodies Mamalaki, A.;N. Trakas;S. J. Tzartos
  17. Nature Biotechnol v.15 Potent 2'-amino, and 2'-fluoro-2'deoxyribonucleotide RNA inhibitors of keratinocyte growth factor Pagratis, N. C.;C. Bell;Y.-F. Chang;S. Jennings;T. Fitzwater;D. Jellinek;C. Dang
  18. Science v.253 Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes Pieken, W. A.;D. B. Olsen;F. Benseler;H. Aurup;F. Eckstein
  19. J. Autoimmun v.2 Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenia gravis Sophianos, D.;S. Tzartos
  20. Carcinogenesis v.10 Characterization of the human cell line TE671 Stratton, M. R.;J. Darling;G. J. Pikington;P. L. Lantos;B. R. Reeves;C. S. Cooper
  21. Science v.249 Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Tuerk, C.;L. Gold
  22. J. Biol. Chem v.256 Mapping of surface structures of electrophorous acetylcholine receptor using monoclonal antibodies Tzartos, S. J.;D. E. Rand;B. L. Einarson;J. M. Lindstrom
  23. Proc. Natl. Acad. Sci. USA v.79 Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies Tzartos, S, J,;M. E. Seybold;J. M. Lindstrom
  24. Proc. Natl. Acad. Sci. USA v.97 Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide Venkatesh, N.;S.-H. Im;M. Balass;S. Fuchs;E. Katchalski-Katzir
  25. Ann. N. Y. Acad. Sci v.505 Antibody heterogeneity and specificity in myasthenia gravis Vincent, A.;P. J. Whiting;M. Schluep;F. Heidenreich;B. Lang;A. Roberts;N. Willcox;J. Newson-Davis